Pages that link to "Q36402111"

The following pages link to Metformin extended release treatment of adolescent obesity: a 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up (Q36402111):

Displaying 43 items.

• The therapy of insulin resistance in other diseases besides type 2 diabetes (Q26822399) (← links)
• Drug interventions for the treatment of obesity in children and adolescents (Q28279770) (← links)
• Metformin use in children with obesity and normal glucose tolerance--effects on cardiovascular markers and intrahepatic fat. (Q30413605) (← links)
• The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial (Q33566838) (← links)
• An evolving scientific basis for the prevention and treatment of pediatric obesity (Q34028763) (← links)
• Practical Approaches to the Treatment of Severe Pediatric Obesity (Q34076989) (← links)
• Carbohydrate modified diet & insulin sensitizers reduce body weight & modulate metabolic syndrome measures in EMPOWIR (enhance the metabolic profile of women with insulin resistance): a randomized trial of normoglycemic women with midlife weight gai (Q34258486) (← links)
• Effects of metformin on body weight and body composition in obese insulin-resistant children: a randomized clinical trial (Q34527061) (← links)
• AMPK as Target for Intervention in Childhood and Adolescent Obesity (Q34557477) (← links)
• A cross-sectional study of osteocalcin and body fat measures among obese adolescents (Q34742767) (← links)
• Effects of metformin on energy intake and satiety in obese children (Q35171164) (← links)
• Pediatric obesity: etiology and treatment (Q35678445) (← links)
• Assessment of metformin as an additional treatment to therapeutic lifestyle changes in pediatric patients with metabolic syndrome (Q36099847) (← links)
• Sex hormone-binding globulin, oligomenorrhea, polycystic ovary syndrome, and childhood insulin at age 14 years predict metabolic syndrome and class III obesity at age 24 years (Q36160966) (← links)
• Pharmacotherapy for childhood obesity: present and future prospects (Q36468087) (← links)
• Predictors of weight-loss response with glucagon-like peptide-1 receptor agonist treatment among adolescents with severe obesity (Q36485989) (← links)
• Exenatide as a Weight‐Loss Therapy in Extreme Pediatric Obesity: A Randomized, Controlled Pilot Study (Q36934365) (← links)
• Effects of a Comprehensive, Intensive Lifestyle Intervention Combined with Metformin Extended Release in Obese Adolescents. (Q36979445) (← links)
• Evaluation of differential effects of metformin treatment in obese children according to pubertal stage and genetic variations: study protocol for a randomized controlled trial (Q37106506) (← links)
• A longitudinal study of serum insulin and insulin resistance as predictors of weight and body fat gain in African American and Caucasian children (Q37553110) (← links)
• Assessment and management of obesity in childhood and adolescence (Q37942290) (← links)
• Treatment of obesity-related hypertension in children and adolescents (Q38087932) (← links)
• Topiramate for weight reduction in adolescents with severe obesity (Q38229824) (← links)
• Pharmacotherapy in the Management of Pediatric Obesity (Q38667323) (← links)
• Pediatric obesity pharmacotherapy: current state of the field, review of the literature and clinical trial considerations. (Q38817489) (← links)
• An Integrative Analysis of the Effect of Lifestyle and Pharmacological Interventions on Glucose Metabolism in the Prevention and Treatment of Youth-Onset Type 2 Diabetes (Q38886919) (← links)
• Effect of phentermine on weight reduction in a pediatric weight management clinic (Q38989047) (← links)
• The Effect of Eighteen-Month Metformin Treatment in Obese Adolescents: Comparison of Results Obtained in Daily Practice with Results from a Clinical Trial. (Q39013480) (← links)
• The "slower" the better. (Q39107512) (← links)
• Long-term treatment with metformin in obese, insulin-resistant adolescents: results of a randomized double-blinded placebo-controlled trial (Q41085122) (← links)
• Treatment of obesity in children and adolescents (Q41777831) (← links)
• Carbohydrate metabolism disorders among obese children and adolescents. Diabetes mellitus type 2 (Q44060809) (← links)
• Omega-3 polyunsaturated fatty acids reduce insulin resistance and triglycerides in obese children and adolescents (Q45157488) (← links)
• Pediatric Obesity-Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline. (Q47762246) (← links)
• Metformin in the treatment of obese children and adolescents at risk of type 2 diabetes (Q50474740) (← links)
• Long-term metformin treatment in adolescents with obesity and insulin resistance, results of an open label extension study (Q58756822) (← links)
• The effects of metformin on insulin resistance in overweight or obese children and adolescents: A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials (Q61809477) (← links)
• Advances in pediatric pharmacology, therapeutics, and toxicology (Q84567620) (← links)
• Treatment of Obesity in Young People-a Systematic Review and Meta-analysis (Q88801540) (← links)
• Efficacy of Metformin Treatment with Respect to Weight Reduction in Children and Adults with Obesity: A Systematic Review (Q90236640) (← links)
• Role of metformin in overweight and obese people without diabetes: a systematic review and network meta-analysis (Q90236672) (← links)
• Effects of metformin administration on endocrine-metabolic parameters, visceral adiposity and cardiovascular risk factors in children with obesity and risk markers for metabolic syndrome: A pilot study (Q91843534) (← links)
• Rationale and design of a pilot study to evaluate the acceptability and effectiveness of a revised protein sparing modified fast (rPSMF) for severe obesity in a pediatric tertiary care weight management clinic (Q92736978) (← links)